GleamWall
中文EN

BEAM Beam Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745999 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY163.3%
TTM net income YoY74.1%
TTM EPS YoY80.0%
Revenue 3-yr CAGR21.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-267.7%
Net margin-73.0%
FCF margin-271.6%
EBITDA margin-252.6%

Returns

ROE-11.1%
ROA-8.3%
ROIC (approx.)-40.2%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets24.9%
Debt / equity0.11x
Current ratio13.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.63x
Accruals ratio21.8%
Payout ratio—
Capex / revenue6.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$307,000$490,000$31.74M$114.11M$9.70M$8.47M$7.47M$30.07M
R&D expense$110.11M$95.10M$104.52M$99.28M$109.77M$101.76M$98.82M$101.44M
SG&A expense$31.52M$31.95M$34.43M$32.28M$26.74M$26.86M$27.94M$28.66M
Operating income-$141.32M-$126.55M-$107.22M-$17.45M-$126.81M-$120.15M-$119.29M-$100.04M
Pretax income———$244.30M-$112.73M-$102.29M—-$90.35M
Income tax$0$0$0$0$0$0$0$0
Net income-$134.41M-$122.68M-$94.32M$244.30M-$112.57M-$102.14M-$108.33M-$90.35M
EBITDA-$135.88M-$121.14M-$101.61M-$11.78M-$121.25M-$114.61M-$113.76M-$94.59M
EPS (basic)-1.28-1.18-0.91—-1.10-1.00-1.23—
EPS (diluted)-1.28-1.18-0.91—-1.10-1.00-1.23—
Weighted avg. shares (diluted)104.70M104.33M103.26M—102.57M102.00M87.98M—
Balance sheet
Cash & equivalents$213.27M$219.82M$288.29M$294.94M$267.96M$282.13M$527.91M$290.11M
Short-term investments$830.61M$933.10M$923.36M$950.27M$807.01M$868.21M$692.04M$568.77M
Current assets$1.07B$1.18B$1.27B$1.27B$1.10B$1.18B$1.25B$878.15M
PP&E, net$94.04M$97.61M$101.25M$104.50M$108.29M$108.82M$109.57M$111.41M
Total assets$1.27B$1.39B$1.48B$1.48B$1.31B$1.39B$1.47B$1.10B
Current liabilities$82.08M$80.88M$74.56M$96.94M$182.56M$174.13M$141.55M$182.07M
Long-term debt$100.36M$100.26M$100.19M—————
Total debt$100.36M$100.26M$100.19M—————
Total liabilities$316.40M$318.91M$316.36M$242.82M$345.08M$344.34M$343.78M$370.28M
Shareholders' equity$952.67M$1.07B$1.16B$1.24B$972.66M$1.05B$1.13B$733.54M
Net debt-$112.90M-$119.57M-$188.10M—————
Shares outstanding103.44M103.26M102.74M101.75M101.36M100.76M100.56M83.63M
Cash flow statement
Operating cash flow-$110.75M-$66.10M-$128.51M-$83.29M-$81.48M-$76.45M-$103.88M-$76.36M
Capital expenditure$1.21M$2.41M$2.23M$3.73M$5.01M$3.14M$3.06M$2.97M
Free cash flow-$111.96M-$68.51M-$130.75M-$87.02M-$86.49M-$79.59M-$106.95M-$79.33M
Investing cash flow$101.86M-$9.88M$25.27M$108.41M$65.66M-$170.41M-$125.09M$126.28M
Financing cash flow$2.33M$7.52M$96.61M$1.89M$1.68M$1.11M$473.38M$3.44M
Depreciation & amortization$5.45M$5.41M$5.61M$5.67M$5.56M$5.54M$5.53M$5.44M
Stock-based compensation$18.55M$19.28M$19.04M$20.45M$22.75M$24.37M$26.68M$30.22M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.